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In the current issue of Liver Transplantation, the out-
comes of adult patients with acute liver failure (ALF) in 
the United States listed as status 1 for liver transplanta-
tion (LT) between 2002 and 2016 are presented.(1) Key 
findings include the following: (1) black patients with 
ALF had higher Model for End-Stage Liver Disease 
scores and a lower likelihood of spontaneous recovery 
compared with whites with a larger proportion undergo-
ing LT and (2) black patients had a lower 1-year survival 
after transplantation. These provocative findings con-
firm prior reports that wait-list mortality and post-LT 
outcomes vary by race and that the number of adults with 
ALF being referred for LT appears to have declined.(2,3)
Liver Transplantation  
for ALF
ALF is a rare clinical syndrome defined by the sud-
den onset of coagulopathy and mental status changes 
in a patient without known prior liver disease. 
Patients with ALF are at high risk for dying and 
currently account for ~3% of the liver transplants in 
the United States. The Acute Liver Failure Study 
Group (ALFSG) is a multicenter National Institutes 
of Health network that has been prospectively study-
ing the etiologies and outcomes of ALF since 1998.(2) 
The ALFSG has demonstrated that patients with ac-
etaminophen (APAP) overdose and hepatitis A virus 
(HAV)–related ALF have a much greater likelihood of 
transplant-free survival compared with patients with 
idiosyncratic drug-induced liver injury (DILI) and au-
toimmune hepatitis (AIH; Table 1).(2) Furthermore, 
the proportion of ALFSG patients being listed as well 
as undergoing emergency LT significantly declined in 
the United States between 2002 and 2016 (Fig. 1).(2) 
Whether these trends are due to more rapid diag-
nosis and treatment with effective therapies, such as 
N-acetylcysteine for APAP and non-APAP etiologies 
or less frequent use of blood products and mechanical 
ventilation, is unclear.
In addition, US Food and Drug Administration 
regulatory actions to reduce the amount of APAP in 
narcotic analgesic congeners and over-the-counter 
formulations may be having a favorable impact, but 
APAP hepatotoxicity remains the leading cause of 
ALF in the United States. An alternative explanation 
for the observed decline in status 1 listings could be 
improved categorization of patients as true ALF cases 
versus acute-on-chronic liver failure. Although 40% of 
the status 1 patients were coded as “unknown” etiol-
ogy by the United Network for Organ Sharing, it is 
unlikely that these patients truly had indeterminate 
ALF in light of recent studies that use formal causality 
assessment.(4) Therefore, there is no convincing evi-
dence that the etiologies nor incidence of ALF have 
substantially changed in the past 20 years in the United 
States. However, it remains plausible that the medical 
management of these critically ill patients is globally 
improving with fewer requiring transplant listing and 
undergoing LT.(2)
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Wait-List Outcomes Among 
Status 1 Patients
Although the proportion of ALF patients listed 
as status 1 has significantly declined over the past 
15 years, black patients remain overrepresented com-
pared with other racial groups. Furthermore, black 
ALF patients had a greater likelihood of dying or 
deteriorating prior to LT on univariate analysis but 
not when taking into account the competing risk of 
transplant. The greater need for LT in black ALF 
patients may, in part, be driven by their greater likeli-
hood of having a diagnosis of DILI, AIH, or hepati-
tis B virus (HBV) that are all associated with a lower 
rate of spontaneous recovery compared with APAP 
overdose that predominates among white ALF pa-
tients. In support of this possibility, white ALF pa-
tients were also more likely to be removed from the 
waiting list due to clinical improvement.
The higher rate of LT among black ALF patients may 
also be related to racial differences in the likelihood of 
developing and presenting with severe DILI and AIH. 
The ALFSG showed that blacks were significantly 
more likely to present with idiosyncratic DILI com-
pared with whites (24.4% versus 14.9%, P = 0.009).(5) 
Recent European studies have also demonstrated that 
black patients with AIH present with more severe liver 
injury and are more likely to require transplant or die 
during follow-up.(6) Prospective studies of idiosyn-
cratic DILI have also suggested that black patients are 
more likely to have poorer clinical outcomes including 
higher short-term mortality compared with whites.(7,8) 
The reasons for the poorer outcomes when controlling 
for disease etiology are unknown but could be medi-
ated by genetic or immunological factors.
Posttransplant Outcomes in 
Status 1 ALF Patients
The 1-year survival of ALF transplant recipients sig-
nificantly differed by patient race (79.6% black versus 
82.8% white and 89.3% Asian; P = 0.02). The superior 
outcomes among Asian ALF LT recipients are simi-
lar to prior studies demonstrating better outcomes in 
Asians with chronic HBV undergoing LT compared 
with other groups.(9) Although the median time to LT 
was similar across all racial groups at 2 days, the pres-
ence and severity of cerebral edema and infections at the 
time of LT were not available for analysis. Furthermore, 
other donor factors (age, cold ischemia time, and ABO 
compatibility) and recipient factors (age and use of in-
duction immunosuppression) that may have impacted 
outcomes were also not available to review.(10)
Prior studies have demonstrated lower 1-year sur-
vival among black patients with cirrhosis undergoing 
LT compared with whites.(11) Interestingly, donor-re-
cipient race matching may be particularly important 
for black LT recipients with hepatocellular carcinoma 
and cirrhosis as has been shown for black recipients 
of kidney, lung, and heart transplant.(12,13) However, 
it is unlikely that matching by donor race will be 
taBlE 1. Etiologies and outcomes in adult alF patients
Etiology Recommended Treatment Spontaneous Survival
Favorable etiology*
APAP (50%) N-acetylcysteine, nasogastric lavage, and activated charcoal† 70%-80%
Ischemia (5%-10%) Pressors, fluids 50%-60%
HAV (1%-3%) N-acetylcysteine 60%-70%
Pregnancy (1%-3%) Emergent delivery 50%-60%
Unfavorable etiology*
Idiosyncratic DILI (5%-10%) N-acetylcysteine 20%-30%
Indeterminate (5%-10%) N-acetylcysteine 20%-30%
HBV (1%-3%) Entecavir/tenofovir 20%-30%
N-acetylcysteine
Autoimmune (5%) Corticosteroids 20%-30%
N-acetylcysteine
Wilson’s disease (<1%) Chelation <5%
*The percentages represent the proportion of adult ALF patients with that particular etiology.
†For single time point ingestions <12 hours.
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feasible under the emergency circumstances encoun-
tered in status 1 ALF patients. Nonetheless, if an 
immunological basis for the differences in outcomes is 
demonstrated, immunosuppression protocols could be 
adapted in future race mismatched status 1 ALF trans-
plant recipients.
In closing, Nephew et al. provide interesting and 
useful data regarding the incidence, etiologies, and 
outcomes of a large cohort of critically ill patients with 
a rare disease (ie, ALF) being cared for in more than 
100 LT programs around the country.(1) The significant 
decline in the listing of ALF patients as status 1 is good 
news for the general population and the many patients 
with cirrhosis awaiting LT.(2) The higher rate of trans-
plantation among black patients is likely due to their 
greater likelihood of having a nonrecoverable cause of 
ALF (ie, DILI or AIH) rather than being due to other 
clinical management issues or biases. Although 1-year 
survival after LT varied by patient race and ethnicity, 
the current analyses did not take into account other 
potential confounders that may have influenced out-
comes. Additional prospective studies are now needed 
to identify modifiable recipient or donor factors that 
could lead to further improvements in ALF patient 
outcomes across all racial groups.
robert J. Fontana, M.d.1 
valerie durkalski, ph.d.2
1 division of Gastroenterology and Hepatology  
university of Michigan  
ann arbor, Mi
2 department of public Health sciences  
Medical university of south Carolina  
Charleston, sC
FiG. 1. Listing and receipt of liver transplantation in adult patients enrolled in the US ALFSG registry between 2002 and 2016. The 
proportion of ALF patients being listed and undergoing emergency LT both significantly declined over time (by Cochran-Armitage test).
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